Anaemia in cancer: Pathophysiology and treatment

Cancer Treatment Reviews

Volumn 26, Issue 4, 2000, Pages 303-311

  Mercadante, Sebastiano ^a   Gebbia, V ^a   Marrazzo, A ^a   Filosto, S ^a  

^a LA MADDALENA CANCER CENTER   (Italy)

Author keywords

Anaemia; Blood transfusion; Cancer; Erythropoietin; Palliative care

Indexed keywords

ERYTHROPOIETIN;

ADVANCED CANCER; ANEMIA; BLOOD TRANSFUSION; BONE MARROW; CANCER; HIGH RISK PATIENT; LIFE EXPECTANCY; PATHOPHYSIOLOGY; REVIEW;

EID: 0034254503     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1053/ctrv.2000.0181     Document Type: Review

References (53)

1. Johnston E., Crawford J. The haematologic support of the cancer patient. Berger A., Portenoy R. K., Weissman D. E. Supportive Oncology. 1998;549-569 Lippincott-Raven Publishers, Philadelphia.
2. Skilling J. R., Rogers-Melamed I., Nabholtz J. M. An epidemiological review of anaemia in cancer chemotherapy in Canada. Proceedings of the European Conference on Clinical Oncology and Cancer Nursing European Society of Therapeutic Radiology and Oncology. 1995;S813.
3. Leitgeb C., Pecherstorfer M., Fritz E., Ludwig H. Quality of life in chronic anaemia of cancer during treatment with recombinant human erythropoietin. Cancer. 73:1994;2535-2542.
4. Durei B. G., Salmon S. E. A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 36:1997;842-854.
5. Manegold C. The causes and prognostic significance of low haemoglobin levels in tumour patients. Strahlenher Onkol. 174:1998;17-19.
6. Nowrousian M. R., Kasper C., Oberhoff C., Essers U., Voigtmann R., Gallash W., Quarder O. Pathophysiology of cancer-related anaemia. Smith J. F., Boogaerts M. A., Ehmer B. rhErythropoietin in Cancer Supportive Treatment. 1996;13-34 Marcel Dekker Inc, New York.
7. Van Zant G., de Haan G., Rich I. N. Alternatives to stem cell renewal from a development viewpoint. Exp Hematol. 25:1997;187-192.
8. Silva M., Grillot D., Benito A. Erythropoietin can promote erythoid progenitor survival by repressing apoptosis through Bcl-XL and Bcl-2. Blood. 88:1996;1576-1582.
9. Tan C. C., Eckardt K. U., Firth J. D. Feedback modulation of renal and hepatic erythropoietin mRNA in response to graded anaemia and hypoxia. Am J Physiol. 263:1992;F474-F481.
10. Kouri M. J., Bondurant M. C. A survival model of erythropoietin action. Science. 248:1990;378-381.
11. Jones J. A. Red blood cell substitutes: current status. Br J Anaesth. 74:1995;697-703.
12. Mikami Y., Mikami M., Nannmoku H. Anaemia-inducing factor expressed in gastric cancer is homologous with complement regulatory factor CD59. J Exp Clin Cancer Res. 17:1998;355-360.
13. Cash J. M., Sears D. A. The anaemia of chronic disease: spectrum of associated diseases in a series of unselected hospitalized patients. Am J Med. 87:1989;638-644.
14. Means R. T., Krantz S. B. Progress in understanding the pathogenesis of the anaemia of chronic disease. Blood. 80:1992;1639-1647.
15. Faquin W. C., Schneider T. J., Goldberg M. A. Effect of inflammatory cytokines on hypoxia-induced erythopoietin production. Blood. 79:1992;1987-1994.
16. Henry D. H. Changing patterns of care in the management of anaemia. Semin Oncol. 19:1992;3-7.
17. Piroso E., Erslev A. J., Caro J. Inappropriate increase in erythropoietin titres during chemotherapy. Am J Hematol. 32:1989;248-254.
18. Frenkel E. P., Bick R. L., Rutherford C. J. Anaemia of malignancy. Hematol Oncol Clin North Am. 10:1996;861-873.
19. Montserrat E., Bosch F., Rozman C. B-cell chronic lymphocytic leukaemia: recent progress in biology, diagnosis, and therapy. Ann Oncol. 8:1997;93-101.
20. Frommhold H., Guttenberger R., Henke M. The impact of blood haemoglobin content on the outcome of radiotherapy. The Freiburg experience. Strhlenther Onkol. 174:1998;31-34.
21. Lavey R. S. Clinical trial experience using erythropoietin during radiation therapy. Strahlenher Onkol. 174:1998;24-30.
22. Lee W. R., Berkey B., Marcial V. Anaemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma: a secondary analysis of RTOG 85-27. Int J Radiat Oncol Biol Phys. 42:1998;1069-1075.
23. Moliterno A. R., Spivak J. L. Anaemia of cancer. Hematol Oncol Clin North Am. 10:1996;345-363.
24. Lipschitz D. Age-related declines in haematopoietic reserve capacity. Semin Oncol. 22:1995;3-5.
25. Erslev A. J., Caro J., Schuster S. J. Is there an optimal haemoglobin level? Transfusion Med News. 3:1989;237-242.
26. Walker R. H. Special report: transfusion risks. Am J Clin Pathol. 88:1987;374-378.
27. Perkins H. A. Transfusion-induced immunologic unresponsiveness. Trans Med Rev. 2:1988;196-203.
28. Schriemer P. A., Longnecker D. E., Mintz P. D. The possible immunosuppressive effects of perioperative blood transfusion in cardiac patients. Anesthesiology. 68:1988;422-428.
29. Quirt I., Micucci S., Moran L. A., Pater J., Browman G. Erythropoietin in the management of patients with nonhaematologic cancer receiving chemotherapy. Systemic Treatment Program Committee. Cancer Prev Control. 1:1997;241-248.
30. Abels R. I. The use of recombinant human erythopoietin in the treatment of anaemia in patients who have cancer. Semin Oncol. 19:1992;29-35.
31. Wurnig C., Windhager R., Scwameis E. Prevention of chemotherapy-induced anaemia by the use of erythropoietin in patients with primary malignant bone tumors (a double-blind, randomized, phase III study). Transfusion. 36:1996;155-159.
32. Voigtmann R., Nowrousian M. R., Essers U. rhEPO in the treatment of anaemia associated with malignancy. Smith J. F., Boogaerts M. A., Ehmer B. rhErythropoietin in Cancer Supportive Treatment. 1996;113-127 Marcel Dekker Inc, New York.
33. Jilani S. M., Glaspy J. A. Impact of epoetin alfa in chemotherapy-associated anaemia. Semin Oncol. 25:1998;571-576.
34. Glaspy J., Bukowski R., Steinberg D. Impact of therapy with epoietin alpha on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol. 15:1997;1218-1234.
35. Cazzola M., Messinger D., Battistel V. Recombinant human erythropoietin in the anaemia associated with multyple myeloma or non-Hodgkin lymphoma: dose finding and identification of predictors of response. Blood. 86:1995;4446-4453.
36. Ludwig H., Frtz E., Leitgeb C., Percherstofer M., Samonigg H., Schuster J. Prediction of response to erythropoietin treatment in chronic anaemia of cancer. Blood. 84:1994;1056-1063.
37. Birgegard G. rhEPO treatment for the anaemia of multiple myeloma and non-Hodgkin's lymphoma. Smith J. F., Boogaerts M. A., Ehmer B. rhErythropoietin in Cancer Supportive Treatment. 1996;85-98 Marcel Dekker Inc, New York.
38. Crawford J., Blackwell S., Shoemaker D. Prevention of chemotherapy-related anaemia by recombinant human erythopoietin (EPO) in patients with small cell lung cancer receiving cyclophosphamide, doxorubicin, and etoposide (CAE) chemotherapy with G-CSF support. Lung Cancer. 18(Suppl 1):1997;205.
39. Adamson J. W., Ludwig H. Predicting the haematopoietic response to recombinant human erythropoietin (Epoetin alfa) in the treatment of the anaemia in cancer. Oncology. 56:1999;46-53.
40. Griggs J. J., Blumberg N. Recombinant erythropoietin and blood transfusions in cancer chemotherapy-induced anaemia. Anticancer Drugs. 9:1998;925-932.
41. Ortega A., Dranitsaris G., Puodziunas A. A clinical and economic evaluation of red blood cell transfusions in patients receiving cancer chemotherapy. Int J Technol Assess Heath Care. 14:1998;788-798.
42. Ortega A., Dranitsaris G., Puodziunas A. L. What are cancer patients willing to pay for prophylactic epoetin alfa? A cost-benefit analysis. Cancer. 83:1998;2588-2596.
43. Barosi G., Liberato N. L. The cost-effectiveness of rhEPO use in anaemia of cancer. Smith J. F., Boogaerts M. A., Ehmer B. rhErythropoietin in Cancer Supportive Treatment. 1996;45-57 Marcel Dekker Inc, New York.
44. Meadowcroft A. M., Gilbert C. J., Maravich-May D., Hayward S. L. Cost of managing anaemia with and without prophylactic epoetin alfa therapy in breast cancer patients receiving combination chemotherapy. Am J Health Syst Pharm. 55:1998;1898-1902.
45. Stockelberg D., Lehtola P., NorÈn I. Palliative treatment at home for patients with haematological disorders. Support Care Cancer. 5:1997;506-508.
46. Sciortino A. D., Carlton D. C., Axelrod A., Zhukovski D. S., Vinciguerra V. The efficacy of administering blood transfusions at home to terminally ill cancer patients. J Palliat Care. 9:1993;14-17.
47. Gleeson C., Spencer D. Blood transfusion and its benefit in palliative care. Palliat Med. 9:1995;307-313.
48. Monti M., Castellani L., Berlusconi A., Cunietti E. Use of red blood cell transfusions in terminally ill cancer patients admitted to a palliative care unit. J Pain Symptom Manage. 12:1996;18-22.
49. Gagnon B., Mancini I., Pereira J., Bruera E. Palliative management of bleeding events in advanced cancer patients. J Palliat Care. 14:1998;50-54.
50. Dean A. Fibrinolytic inhibitors for cancer-associated bleeding problems. J Pain Symptom Manage. 13:1997;20-24.
51. Regnard C., Makin W. Management of bleeding in advanced cancer - a flow diagram. Palliat Med. 6:1992;74-78.
52. Lassauniere J. M., Bertolino M., Hinault M. Platelet transfusions in advanced haematological malignancies: a position paper. J Palliat Care. 12:1996;38-41.
53. Singer Y., Shvartzman. The feasibility and advisability of administering home blood transfusioins to the terminally ill patient. J Palliat Care. 14:1998;46-48.